CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
Executive Summary
Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.
You may also be interested in...
Medicare Advisers Endorse Patient Reported Outcomes For CAR-T With Caveats
Medicare Evidence Development and Coverage Advisory Committee votes that four existing tools are valid and could be “generalizable” to Medicare beneficiaries.
CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting
Focus is in line with past US Medicare advisory panel meetings on other diseases.
CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting
Focus is in line with past US Medicare advisory panel meetings on other diseases.